Roche Holding AG
ROG#102 of 134 by buybacksSW · Healthcare · Drug Manufacturers - General · Switzerland
roche.comBuybacks · FY2025CHF 987M≈ $1.19B · reported in CHF
Buyback yield0.4%repurchases ÷ market cap
Dividends · FY2025CHF 8.38Bdividend yield 3.3%
Shareholder yield3.7%buybacks + dividends ÷ market cap
Shares outstanding · 5 yr−7.0%803M shares (2025)
Buybacks ÷ free cash flow7%payout incl. dividends 67%
Fiscal-year detail
From the cash-flow statement as reported, in CHF. Negative repurchases mean net share issuance.
| Fiscal year | Repurchases | Dividends | Free cash flow |
|---|---|---|---|
| FY2025Dec 2025 | CHF 987M | CHF 8.38B | CHF 14.1B |
| FY2024Dec 2024 | CHF 1.13B | CHF 7.65B | CHF 15.1B |
| FY2023Dec 2023 | CHF 1.14B | CHF 7.59B | CHF 11.4B |
| FY2022Dec 2022 | CHF 1.26B | CHF 7.45B | CHF 13.3B |
| FY2021Dec 2021 | CHF 19.0B | CHF 7.77B | CHF 16.0B |
| FY2020Dec 2020 | CHF 2.13B | CHF 7.70B | CHF 11.5B |
| FY2019Dec 2019 | CHF 1.01B | CHF 7.45B | CHF 18.9B |
Repurchases in FY2025 were −12.7% versus the prior year.
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19,…
- Market cap
- CHF 256B
- P/E (trailing)
- 20.1×
- Fiscal year end
- December
- ISIN
- CH0012032048
- Reporting currency
- CHF
- Data updated
- Mar 25, 2026